Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli. Mirum has multiple potential catalysts on the way in 2026. In several important ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor, is approved for the treatment of cholestatic pruritus in ...

- Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (MIRM) today reported financial ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible ...

Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year. A recent acquisition could also negatively affect the bottom line.

Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, ...